(VIANEWS) – The NASDAQ opens in less than one hour and Exact Sciences‘s pre-market value is already 10.92% up.
Exact Sciences’s last close was $70.41, 30.13% below its 52-week high of $100.77.
The last session, NASDAQ ended with Exact Sciences (EXAS) rising 1.95% to $70.41. NASDAQ jumped 0.11% to $16,396.83, following the last session’s upward trend on what was a somewhat bullish trend trading session.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Earnings Per Share
As for profitability, Exact Sciences has a trailing twelve months EPS of $-1.13.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.6%.
Moving Average
Exact Sciences’s value is above its 50-day moving average of $64.25 and below its 200-day moving average of $74.32.
More news about Exact Sciences (EXAS).
